Three Fred Hutch Cancer Center research groups recently received prestigious R01 awards from the National Institutes of Health. These multi-million-dollar grants provide up to five years of support for large, multi-year investigations with clear outcomes and high potential for public health benefit. This crop of awards highlights the biostatistical chops in Fred Hutch's Vaccine and Infectious Disease Division, or VIDD. The scientists, who all received R01 funding from the National Institute of A

Beijing-based Syneron Bio has closed a USD 150 million Series B financing round to advance its macrocyclic peptide drug discovery platform and accelerate its pipeline toward clinical development across oncology, autoimmune, metabolic, and rare diseases. The round was co-led by an unnamed international life sciences fund, Decheng Capital, and CDH VGC. Additional participants included a wholly owned subsidiary of the Abu Dhabi Investment Authority, True Light Capital — an independent subsidiary of

A newly identified gene mutation may help explain why schizophrenia patients struggle to update their understanding of reality. The mutation disrupts a brain circuit involved in flexible decision-making, causing mice to stick with outdated choices even when conditions change. Researchers pinpointed the issue to a key thalamus–prefrontal cortex pathway. By reactivating this circuit, they were able to restore normal behavior—raising hope for future therapies.A common feature of schizophrenia is di

Vedanta Biosciences reported that an independent data monitoring committee has recommended the Phase III RESTORATiVE303 trial of VE303 continue without modification following a prespecified interim analysis, with the DMC determining that efficacy exceeded the futility threshold and no new safety signals had emerged. RESTORATiVE303 is a randomized, double-blind, placebo-controlled, multinational Phase III trial enrolling patients at high risk for recurrent Clostridioides difficile infection (CDI)

DARPA-validated company is already manufacturing essential medicine APIs entirely on U.S. soil MESA, Ariz., April 2, 2026 /PRNewswire/ -- Bright Path, a U.S.-based advanced pharmaceutical manufacturer, today welcomed President Trump's proclamation imposing tariffs of up to 100 percent on imported patented pharmaceuticals and active pharmaceutical ingredients (APIs) under Section 232 of the Trade Expansion Act. The proclamation, which the President signed today citing threats to national security

Collaboration connects AI-powered digital behavioral health platform, Syrenity, with licensed therapists to deliver seamless, affordable care CARMEL, Ind., April 2, 2026 /PRNewswire/ -- Syra Health Corp. (OTCQB: SYRA) ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today a partnership with Nora Mental Health to expand access to mental and behavioral health serv

Arvix Biologics outlines the structure of its BioMatrix™ platform, integrating Base, Core, and Prime within a unified biologic system. SUNRISE, FL, UNITED STATES, April 2, 2026 / EINPresswire.com / -- Arvix Biologics outlined the modular architecture of its BioMatrix™ platform, a biologic system designed to support consistent use across surgical and wound-care workflows. The BioMatrix™ platform is organized around three core components — Base, Core, and Prime — structured to function within a un

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continue to drive drug discovery and development and empower AI training algorithms to deliver digital health solutions of the future for consumers, patients and providers TARRYTOWN, N.Y. and CAMBRIDGE, Mass., A

NEW YORK, April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 2,857,144 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.70 per share of common stock (or per common stock equivalent in lieu th

REHOVOT, Israel, April 2, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN)(TASE: EVGN) (the " Company", " Evogene"), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the " Letter") from the Nasdaq Stock Market LLC (" Nasdaq"), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing